Rights statement: This is the author’s version of a work that was accepted for publication in Pharmacological Reports. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Reports, 68, 6, 2016 DOI: 10.1016/j.pharep.2016.09.002
Accepted author manuscript, 637 KB, PDF document
Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Escitalopram affects spexin expression in the rat hypothalamus, hippocampus and striatum
AU - Palasz, Artur
AU - Suszka-Świtek, Aleksandra
AU - Filipczyk, Lukasz
AU - Bogus, Katarzyna
AU - Rojczyk, Ewa
AU - Worthington, John Joseph
AU - Krzystanek, Marek
AU - Wiaderkiewicz, Ryszard
N1 - This is the author’s version of a work that was accepted for publication in Pharmacological Reports. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Reports, 68, 6, 2016 DOI: 10.1016/j.pharep.2016.09.002
PY - 2016/12
Y1 - 2016/12
N2 - BackgroundSpexin (SPX) is a recently discovered neuropeptide that exhibits a large spectrum of central and peripheral regulatory activity, especially when considered as a potent anorexigenic factor. It has already been proven that antidepressants, including selective serotonin reuptake inhibitors (SSRI), can modulate peptidergic signaling in various brain structures. Despite these findings, there is so far no information regarding the influence of treatment with the SSRI antidepressant escitalopram on brain SPX expression.MethodsIn this current study we measured SPX mRNA and protein expression in the selected brain structures (hypothalamus, hippocampus and striatum) of rats chronically treated with a 10 mg/kg dose of escitalopram using quantitative Real-Time PCR and immunohistochemistry.ResultsStrikingly, long-term (4 week) drug treatment led to the downregulation of SPX expression in the rat hypothalamus. This supports the hypothesis that SPX may be involved in the hypothalamic serotonin-dependent actions of SSRI antidepressants and possibly also in the central mechanism of body mass increase. Conversely, SPX expression increased in the hippocampus and striatum.ConclusionsThis is the first report of the effects of a neuropsychiatric medication on SPX expression in animal brain. Our findings shed a new light on the pharmacology of antidepressants and may contribute to a better understanding of the alternative mechanisms responsible for antidepressant action.
AB - BackgroundSpexin (SPX) is a recently discovered neuropeptide that exhibits a large spectrum of central and peripheral regulatory activity, especially when considered as a potent anorexigenic factor. It has already been proven that antidepressants, including selective serotonin reuptake inhibitors (SSRI), can modulate peptidergic signaling in various brain structures. Despite these findings, there is so far no information regarding the influence of treatment with the SSRI antidepressant escitalopram on brain SPX expression.MethodsIn this current study we measured SPX mRNA and protein expression in the selected brain structures (hypothalamus, hippocampus and striatum) of rats chronically treated with a 10 mg/kg dose of escitalopram using quantitative Real-Time PCR and immunohistochemistry.ResultsStrikingly, long-term (4 week) drug treatment led to the downregulation of SPX expression in the rat hypothalamus. This supports the hypothesis that SPX may be involved in the hypothalamic serotonin-dependent actions of SSRI antidepressants and possibly also in the central mechanism of body mass increase. Conversely, SPX expression increased in the hippocampus and striatum.ConclusionsThis is the first report of the effects of a neuropsychiatric medication on SPX expression in animal brain. Our findings shed a new light on the pharmacology of antidepressants and may contribute to a better understanding of the alternative mechanisms responsible for antidepressant action.
KW - Spexin
KW - Escitalopram
KW - SSRI
KW - Neuropeptides
KW - Bbrain
U2 - 10.1016/j.pharep.2016.09.002
DO - 10.1016/j.pharep.2016.09.002
M3 - Journal article
VL - 68
SP - 1326
EP - 1331
JO - Pharmacological reports : PR
JF - Pharmacological reports : PR
SN - 1734-1140
IS - 6
ER -